Related Experiment Videos
Acromegaly update--etiology, diagnosis and management
The Western Journal of Medicine
|March 1, 1987
Summary
Acromegaly diagnosis requires growth hormone and somatomedin C tests. Treatment options like surgery, irradiation, and medications (bromocriptine, somatostatin analogs) are reviewed for managing this complex endocrine disorder.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Acromegaly presents unique clinical features but requires specific tests for diagnosis.
- Growth hormone (GH) secretion tests and somatomedin C measurements are crucial for confirmation.
- Understanding the diverse histochemical and ultrastructural forms of somatotropic adenomas is key.
Purpose of the Study:
- To review the etiology of acromegaly, focusing on somatotropic adenomas.
- To discuss the diagnostic approaches, including basal and dynamic GH tests and somatomedin C.
- To evaluate the effectiveness and challenges of current treatment modalities for acromegaly.
Main Methods:
- Review of existing literature on acromegaly etiology, diagnosis, and treatment.
- Analysis of histochemical and ultrastructural characteristics of somatotropic adenomas.
- Evaluation of surgical, radiological, and pharmacological treatment outcomes.
Main Results:
- Ectopic sources of GH-releasing hormone and GH are recognized causes.
- Surgical treatment success rates are tempered by long-term recurrence.
- Bromocriptine and long-acting somatostatin analogs show promise in managing acromegaly.
Conclusions:
- Acromegaly management requires a comprehensive approach considering adenoma type and treatment response.
- Pharmacotherapy, including bromocriptine and somatostatin analogs, offers new avenues for disease control.
- Ongoing research aims to improve long-term outcomes for acromegaly patients.